Blueprint Medicines Co. (NASDAQ:BPMC) Insider Sells $190,515.92 in Stock

Blueprint Medicines Co. (NASDAQ:BPMC) insider Ariel Hurley sold 1,834 shares of the business’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $103.88, for a total transaction of $190,515.92. Following the sale, the insider now owns 14,913 shares of the company’s stock, valued at approximately $1,549,162.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Blueprint Medicines Stock Performance

BPMC opened at $108.78 on Thursday. The business has a 50 day moving average price of $92.44 and a two-hundred day moving average price of $82.00. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.76 and a quick ratio of 3.61. The company has a market capitalization of $6.66 billion, a price-to-earnings ratio of -22.62 and a beta of 0.65. Blueprint Medicines Co. has a 1-year low of $43.89 and a 1-year high of $110.93.

Blueprint Medicines (NASDAQ:BPMC) last announced its earnings results on Thursday, February 15th. The biotechnology company reported ($1.82) earnings per share for the quarter, beating the consensus estimate of ($2.04) by $0.22. Blueprint Medicines had a negative return on equity of 193.48% and a negative net margin of 102.15%. The business had revenue of $71.96 million during the quarter, compared to analysts’ expectations of $67.34 million. During the same quarter last year, the business posted ($2.65) earnings per share. The company’s quarterly revenue was up 85.5% on a year-over-year basis. Research analysts predict that Blueprint Medicines Co. will post -5.38 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Wedbush reaffirmed an “outperform” rating and set a $110.00 price objective on shares of Blueprint Medicines in a research report on Friday, April 26th. JMP Securities upped their target price on Blueprint Medicines from $114.00 to $125.00 and gave the company a “market outperform” rating in a report on Friday, May 3rd. Stifel Nicolaus raised their price target on Blueprint Medicines from $120.00 to $130.00 and gave the stock a “buy” rating in a report on Friday, April 26th. Barclays upped their price objective on Blueprint Medicines from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Friday, May 3rd. Finally, The Goldman Sachs Group boosted their price target on shares of Blueprint Medicines from $121.00 to $168.00 and gave the company a “buy” rating in a report on Monday. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $100.31.

Hedge Funds Weigh In On Blueprint Medicines

Hedge funds have recently made changes to their positions in the business. Headlands Technologies LLC boosted its holdings in Blueprint Medicines by 105.2% during the first quarter. Headlands Technologies LLC now owns 667 shares of the biotechnology company’s stock worth $63,000 after buying an additional 342 shares in the last quarter. Compass Wealth Management LLC acquired a new stake in shares of Blueprint Medicines during the fourth quarter worth $69,000. PNC Financial Services Group Inc. lifted its holdings in shares of Blueprint Medicines by 63.4% during the third quarter. PNC Financial Services Group Inc. now owns 848 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 329 shares during the last quarter. Van ECK Associates Corp boosted its position in shares of Blueprint Medicines by 28.4% in the 4th quarter. Van ECK Associates Corp now owns 872 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 193 shares during the period. Finally, Cutler Group LLC CA increased its stake in Blueprint Medicines by 1,685.7% in the 3rd quarter. Cutler Group LLC CA now owns 1,000 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 944 shares in the last quarter.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.